Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dian Fan

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
JCO Precision Oncology|August 11, 2022
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor InhibitorsHiroki Sato, Daisuke Kubota, Huan Qiao, et al.
Future Oncology (London, England)|December 14, 2023
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced <i>EGFR</i>-mutated NSCLC after a third-generation EGFR TKITony Mok, Pasi A Jänne, Makoto Nishio, et al.
Future Oncology (London, England)|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2022
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228Paul K Paik, Pang-Dian Fan, Besnik Qeriqi, et al.
NPJ Precision Oncology|November 21, 2025
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenograftsAndreu Òdena, Laia Monserrat, Fara Brasó-Maristany, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and ImmunotherapyConor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 8, 2018
<i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomicsPang-Dian Fan, Giuseppe Narzisi, Anitha D Jayaprakash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
Frontiers in Oncology|May 10, 2021
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast CancerTomás Pascual, Mafalda Oliveira, Eva Ciruelos, et al.
Nature Communications|July 11, 2024
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
JCO Precision Oncology|August 11, 2022
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor InhibitorsHiroki Sato, Daisuke Kubota, Huan Qiao, et al.
Future Oncology (London, England)|December 14, 2023
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced <i>EGFR</i>-mutated NSCLC after a third-generation EGFR TKITony Mok, Pasi A Jänne, Makoto Nishio, et al.
Future Oncology (London, England)|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2022
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228Paul K Paik, Pang-Dian Fan, Besnik Qeriqi, et al.
NPJ Precision Oncology|November 21, 2025
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenograftsAndreu Òdena, Laia Monserrat, Fara Brasó-Maristany, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and ImmunotherapyConor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 8, 2018
<i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomicsPang-Dian Fan, Giuseppe Narzisi, Anitha D Jayaprakash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
Frontiers in Oncology|May 10, 2021
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast CancerTomás Pascual, Mafalda Oliveira, Eva Ciruelos, et al.
Nature Communications|July 11, 2024
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, et al.
Pageof 4